Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199351 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT04199351 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 60 participants.
The verdict
NCT04199351, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity
Interventions
- DRUG Placebo
- DRUG AMG 171
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-12-13 |
| Est. Completion | 2021-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04199351
The ClinicalTrials.gov registry entry for NCT04199351 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04199351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04199351 about?
NCT04199351 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity". To assess the safety and tolerability of AMG 171 as single or multiple doses in subjects with obesity
What is the current status of trial NCT04199351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-12-13. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT04199351?
The interventions under investigation include: Placebo (DRUG), AMG 171 (DRUG).
Who is sponsoring clinical trial NCT04199351?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.